New Horizons in the Treatment and Management of Alzheimer’s Disease: Managed Care Considerations on Role of New and Emerging Therapies

 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2023 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2024 to March 1, 2025
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Eisai

Description:
Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Although not all memory loss indicates Alzheimer’s disease, one in ten people over 65 years of age, and over half of those over 85 have Alzheimer’s disease. Currently, 26 million people worldwide have this dementia. By the year 2050, over 15 million Americans may be affected with the disease. Alzheimer’s disease care costs $200 billion annually in the United States alone. Fortunately for patients with Alzheimer's disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been recently made available, giving medical directors and clinicians options for providing patients with significant reductions in clinical decline. With new options on the horizon, it is imperative that managed care physician medical directors, practicing physicians, pharmacists, payers, nurses and other healthcare professionals who manage Alzheimer’s disease patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, and to be prepared if they are made available.

Upon completion of this activity, participants will be able to:

  • Characterize the clinical and economic burden of Alzheimer’s disease (AD) in terms of incidence and prevalence as well as direct and indirect costs, including quality of life

  • Explain the pathophysiology, the progression of AD, and the role of amyloid plaques as a target for treatment

  • Assess recent clinical trial data on the efficacy, safety and mechanisms of action of new and emerging therapies in the management of AD

  • Explore the emerging role of anti-beta-amyloid (Aß) monoclonal antibodies in the management of AD for reduction in clinical decline

  • Analyze the economic burden of AD and disease management programs that aim to reduce healthcare costs and improve quality of life for patients with AD
     

Faculty: Richard S. Isaacson, MD
Director, FAU Center for Brain Health
Schmidt College of Medicine
Florida Atlantic University

As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for the list of disclosures.

Disclosure:

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Isaacson has served as a consultant for Acadia, Biogen, Genentech, and Lilly. All relevant conflicts of interest have been mitigated.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Eisai


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue